Cancer

Cover image for Vol. 122 Issue 11

Early View (Online Version of Record published before inclusion in an issue)

Edited By: Fadlo R. Khuri, MD

Impact Factor: 5.068

ISI Journal Citation Reports © Ranking: 2014: 32/211 (Oncology)

Online ISSN: 1097-0142

Associated Title(s): Cancer Cytopathology, CA: A Cancer Journal for Clinicians

VIEW

  1. 1 - 100
  2. 101 - 106
  1. Original Articles

    1. Disease Site

      Gastrointestinal Disease
      Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma

      Jordan M. Cloyd, Christopher H. Crane, Eugene J. Koay, Prajnan Das, Sunil Krishnan, Laura Prakash, Rebecca A. Snyder, Gauri R. Varadhachary, Robert A. Wolff, Milind Javle, Rachna T. Shroff, David Fogelman, Michael Overman, Huamin Wang, Anirban Maitra, Jeffrey E. Lee, Jason B. Fleming and Matthew H. G. Katz

      Version of Record online: 31 MAY 2016 | DOI: 10.1002/cncr.30117

      • image

      In this single-institution review of patients undergoing preoperative therapy before pancreatoduodenectomy for pancreatic ductal adenocarcinoma, the administration of hypofractionated chemoradiation is associated with margin-negative resection rates, treatment effect, locoregional recurrence, and overall survival similar to those associated with standard fractionated chemoradiation. The use of either preoperative chemoradiation regimen is associated with improved locoregional control (but not overall survival) in comparison with systemic chemotherapy alone.

    2. Head and Neck Disease
      Comparative effectiveness of surgical and nonsurgical therapy for advanced laryngeal cancer

      Chun Chieh Lin, Stacey A. Fedewa, Kara K. Prickett, Kristin A. Higgins and Amy Y. Chen

      Version of Record online: 31 MAY 2016 | DOI: 10.1002/cncr.30122

      • image
      • image

      Complete chemoradiation (CRT) for advanced laryngeal cancer was found to have a similar survival benefit to that of surgery. However, a substantial percentage of patients who initiated CRT did not complete the course. Although CRT provides organ preservation, the benefits and trade-offs between the treatments and the importance of completing the full course of CRT should be fully discussed with patients.

    3. Breast Disease
      Emerging trends in surgical and adjuvant radiation therapies among women diagnosed with ductal carcinoma in situ

      Oyewale O. Shiyanbola, Brian L. Sprague, John M. Hampton, Kim Dittus, Ted A. James, Sally Herschorn, Ronald E. Gangnon, Donald L. Weaver and Amy Trentham-Dietz

      Version of Record online: 31 MAY 2016 | DOI: 10.1002/cncr.30105

      • image

      Recommended guidelines highlight a conservative approach to the management of ductal carcinoma in situ. According to data for women diagnosed with ductal carcinoma in situ in the National Cancer Data Base, the use of adjuvant radiation therapy after breast-conserving surgery has plateaued since 2007, and mastectomy, including reconstruction and removal of the contralateral breast, has increased with demographic variation. See also pages 000-000.

  2. Editorial

    1. Ductal carcinoma in situ: How much is too much?

      Keerthi Gogineni

      Version of Record online: 31 MAY 2016 | DOI: 10.1002/cncr.30107

      In this issue of Cancer, Shiyanbola et al describe changing trends in the treatment of ductal carcinoma in situ. Their findings reinforce the need for research into the natural history of ductal carcinoma in situ that may enable women with low-risk lesions to undergo less invasive treatment. See also pages 000-000.

  3. Original Articles

    1. Disease Site

      Hematologic Malignancies
      Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes

      Gevorg N. Tamamyan, Hagop M. Kantarjian, Jing Ning, Preetesh Jain, Koji Sasaki, Kenneth L. McClain, Carl E. Allen, Sherry A. Pierce, Jorge E. Cortes, Farhad Ravandi, Marina Y. Konopleva, Guillermo Garcia-Manero, Christopher B. Benton, Dai Chihara, Michael E. Rytting, Sa Wang, Waleed Abdelall, Sergej N. Konoplev and Naval G. Daver

      Version of Record online: 31 MAY 2016 | DOI: 10.1002/cncr.30084

      • image
      • image
      • image
      • image

      Malignancy-associated hemophagocytic lymphohistiocytosis (HLH) in adults is frequently associated with hematologic malignancies, and the outcomes are dismal. In this retrospective, single-institute study, the authors analyze the characteristics of 61 adult patients with pathologic evidence of hemophagocytosis and identified new variables that which may aid in the diagnosis of malignancy-associated HLH. The results also confirm the poor outcomes in patients with malignancy-associated HLH.

    2. Gastrointestinal Disease
      Increased incidence of FBXW7 and POLE proofreading domain mutations in young adult colorectal cancers

      Nishi Kothari, Jamie K. Teer, Andrea M. Abbott, Thejal Srikumar, Yonghong Zhang, Sean J. Yoder, Andrew S. Brohl, Richard D. Kim, Damon R. Reed and David Shibata

      Version of Record online: 31 MAY 2016 | DOI: 10.1002/cncr.30082

      • image
      • image
      • image

      The authors describe their original research involving exome sequencing of patients with colorectal cancer in which younger patients were compared with older patients. A unique genetic profile is identified for younger patients that may have implications on future screening and treatment paradigms for these patients.

    3. Hepatobiliary Disease
      Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases

      Georgios A. Margonis, Yuhree Kim, Kazunari Sasaki, Mario Samaha, Neda Amini and Timothy M. Pawlik

      Version of Record online: 31 MAY 2016 | DOI: 10.1002/cncr.30085

      • image
      • image
      • image
      • image

      Overall KRAS mutation is not associated with recurrence-free survival in patients who undergo resection of CRLM. However, KRAS codon 13 mutations are associated with a higher risk for overall extrahepatic recurrence and lung-specific recurrence.

    4. Gynecologic Oncology
      Accuracy of urinary human papillomavirus testing for the presence of cervical human papillomaviruses and higher grades of cervical intraepithelial neoplasia

      Chandrika J. Piyathilake, Suguna Badiga, Michelle M. Chambers, Ilene K. Brill, Roland Matthews and Edward E. Partridge

      Version of Record online: 31 MAY 2016 | DOI: 10.1002/cncr.30123

      • image
      • image
      • image

      The purpose of this study is to determine the accuracy of urinary human papillomavirus (HPV) testing for the presence of cervical HPVs and higher grade cervical intraepithelial lesions. The results demonstrate that urinary HPV testing provides highly satisfactory results for excluding the possibility of any cervical HPV infections, including HPV types not included in vaccines and cervical intraepithelial neoplasia lesions associated with any high-risk HPV, regardless of a woman's age, race, or excess body weight.

    5. Discipline

      Symptom Control and Palliative Care
      Helping parents live with the hole in their heart: The role of health care providers and institutions in the bereaved parents' grief journeys

      Jennifer M. Snaman, Erica C. Kaye, Carlos Torres, Deborah V. Gibson and Justin N. Baker

      Version of Record online: 31 MAY 2016 | DOI: 10.1002/cncr.30087

      Parents of children who die often experience significant psychosocial and health sequelae and may benefit from ongoing support and resources throughout their grief journey. In this article, bereaved parents identify the quintessential components of bereavement support that they believe should be provided by individual members of the medical team and by the institution as a whole.

  4. Correspondence

  5. Original Articles

    1. Discipline

      Disparities Research
      Racial and ethnic differences in patient navigation: Results from the Patient Navigation Research Program

      Naomi Y. Ko, Frederick R. Snyder, Peter C. Raich, Electra D. Paskett, Donald J. Dudley, Ji-Hyun Lee, Paul H. Levine and Karen M. Freund

      Version of Record online: 26 MAY 2016 | DOI: 10.1002/cncr.30109

      • image

      The current study explores whether patient navigation reduces racial and ethnic differences in the time to diagnostic resolution of a cancer screening abnormality. The study demonstrates that patient navigation significantly reduces the median time to diagnostic resolution in black participants, although the reduction does not appear to entirely eliminate disparities between this and other racial and ethnic groups.

    2. Disease Site

      Genitourinary Disease
      Sex disparities in use of chemotherapy and survival in patients with advanced bladder cancer

      Tracy L. Rose, Allison M. Deal, Matthew E. Nielsen, Angela B. Smith and Matthew I. Milowsky

      Version of Record online: 25 MAY 2016 | DOI: 10.1002/cncr.30029

      • image

      Women are less likely than men to receive systemic chemotherapy for advanced bladder cancer, and this difference may partially account for the poorer overall survival observed in women. However, overall survival remains lower in women independent of chemotherapy use. See also pages 000-000.

  6. Editorial

    1. Mind the gap: What is driving the survival disparity between the sexes in bladder cancer?

      Lauren C. Harshman

      Version of Record online: 25 MAY 2016 | DOI: 10.1002/cncr.30027

      Bladder cancer is well known to preferentially afflict men. However, women are significantly more likely to die of the disease even when corrected for stage, tumor characteristics, and age. In this issue of Cancer, Rose and colleagues highlight concerning disparities in bladder cancer treatment and outcomes between the sexes.

      See also pages 000–000.

  7. Original Articles

    1. Disease Site

      Genitourinary Disease
      Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer

      Joshua A. Halpern, Art Sedrakyan, Wei-Chun Hsu, Jialin Mao, Timothy J. Daskivich, Paul L. Nguyen, Encouse B. Golden, Josephine Kang and Jim C. Hu

      Version of Record online: 25 MAY 2016 | DOI: 10.1002/cncr.30101

      • image
      • image

      The use of stereotactic body radiotherapy (SBRT) and proton beam therapy for the treatment of patients with localized prostate cancer in the United States has increased over time. Despite men of lower stage undergoing SBRT, SBRT appears to be associated with greater toxicity but lower health care costs compared with other radiotherapies.

    2. Breast Disease
      You have full text access to this OnlineOpen article
      An observational study to examine changes in metabolic syndrome components in patients with breast cancer receiving neoadjuvant or adjuvant chemotherapy

      Christina M. Dieli-Conwright, Louise Wong, Sarah Waliany, Leslie Bernstein, Behrouz Salehian and Joanne E. Mortimer

      Version of Record online: 24 MAY 2016 | DOI: 10.1002/cncr.30104

      Patients with breast cancer who receive (neo)adjuvant chemotherapy experience an impaired metabolic presentation as noted by worsened components of metabolic syndrome, anthropometrics, and biomarkers of glucose metabolism. Lifestyle interventions such as diet and exercise may be preventive approaches for use during chemotherapy to reduce the onset of metabolic syndrome in patients with breast cancer.

    3. Gastrointestinal Disease
      Predicting advanced neoplasia at colonoscopy in a diverse population with the National Cancer Institute colorectal cancer risk-assessment tool

      Uri Ladabaum, Ashley Patel, Ajitha Mannalithara, Vandana Sundaram, Aya Mitani and Manisha Desai

      Version of Record online: 24 MAY 2016 | DOI: 10.1002/cncr.30096

      • image
      • image
      • image
      • image

      The National Cancer Institute colorectal cancer risk-assessment tool, which was designed to predict future colorectal cancer risk, displays modest discriminatory accuracy in predicting advanced neoplasia at screening colonoscopy in a diverse population. This tool may aid shared decision-making in clinical practice.

    4. Discipline

      Pediatric Oncology
      Parental preparedness for late effects and long-term quality of life in survivors of childhood cancer

      Katie A. Greenzang, Angel M. Cronin and Jennifer W. Mack

      Version of Record online: 24 MAY 2016 | DOI: 10.1002/cncr.30092

      • image
      • image

      The parents of children with cancer believe themselves to be prepared to manage their child's cancer treatment, but they feel less prepared for survivorship. High-quality communication with providers may help parents to feel more prepared for their child's life after cancer therapy.

    5. Diagnostic Imaging
      Second-opinion interpretations of neuroimaging studies by oncologic neuroradiologists can help reduce errors in cancer care

      Vaios Hatzoglou, Antonio M. Omuro, Sofia Haque, Yasmin Khakoo, Ian Ganly, Jung Hun Oh, Amita Shukla-Dave, Robin Fatovic, Joshua Gaal and Andrei I. Holodny

      Version of Record online: 24 MAY 2016 | DOI: 10.1002/cncr.30083

      • image
      • image

      Delivering the highest quality of cancer care is an important issue and must continue to be emphasized. Second-opinion interpretations of neuroimaging studies by subspecialized oncologic neuroradiologists reduce error and optimize the care of cancer patients.

    6. Radiation Oncology
      PMH 9907: Long-term outcomes of a randomized phase 3 study of short-term bicalutamide hormone therapy and dose-escalated external-beam radiation therapy for localized prostate cancer

      Andrew J. McPartlin, Rachel Glicksman, Melania Pintilie, Debbie Tsuji, Gary Mok, Andrew Bayley, Peter Chung, Robert G. Bristow, Mary K. Gospodarowicz, Charles N. Catton, Michael Milosevic and Padraig R. Warde

      Version of Record online: 24 MAY 2016 | DOI: 10.1002/cncr.30093

      • image
      • image
      • image
      • image

      The PMH 9907 trial was a randomized study assessing the outcome of dose-escalated external-beam radiotherapy with or without 5 months neoadjuvant and concurrent bicalutamide 150 mg once daily for 252 patients with localized prostate cancer. After a median follow-up of 9.1 years, a nonsignificant 7% difference in the biochemical failure rate is reported in favor of combination therapy.

    7. Outcomes Research
      Early impact of Medicare accountable care organizations on cancer surgery outcomes

      Lindsey A. Herrel, Edward C. Norton, Scott R. Hawken, Zaojun Ye, Brent K. Hollenbeck and David C. Miller

      Version of Record online: 24 MAY 2016 | DOI: 10.1002/cncr.30111

      • image

      Early hospital participation in the accountable care organization program of the Medicare Shared Savings Program is not associated with greater reductions in adverse perioperative outcomes for patients undergoing a major cancer surgery in comparison with control hospitals. The longitudinal improvements in perioperative outcomes identified during the study interval may reflect the impact of concurrent policies more directly applicable to surgical patients.

    8. Psychosocial Oncology
      Young adult female cancer survivors' unmet information needs and reproductive concerns contribute to decisional conflict regarding posttreatment fertility preservation

      Catherine Benedict, Bridgette Thom, Danielle N. Friedman, Debbie Diotallevi, Elaine M. Pottenger, Nirupa J. Raghunathan and Joanne F. Kelvin

      Version of Record online: 23 MAY 2016 | DOI: 10.1002/cncr.29917

      • image

      Young adult female cancer survivors who maintain their reproductive ability after gonadotoxic treatments report decisional conflict when prompted to consider future fertility preservation. The results of the current study indicate that greater levels of unmet information needs and reproductive concern contribute to increased conflict. Survivorship care should include comprehensive reproductive health counseling and resources to support survivors in making informed, values-based decisions regarding their reproductive options.

    9. Disease Site

      Gastrointestinal Disease
      Colorectal cancer screening: Estimated future colonoscopy need and current volume and capacity

      Djenaba A. Joseph, Reinier G. S. Meester, Ann G. Zauber, Diane L. Manninen, Linda Winges, Fred B. Dong, Brandy Peaker and Marjolein van Ballegooijen

      Version of Record online: 20 MAY 2016 | DOI: 10.1002/cncr.30070

      • image
      • image
      • image

      There is sufficient colonoscopy capacity to screen 80% of the eligible US population with fecal immunochemical testing, colonoscopy, or a mix of tests.

    10. Increased tumor response to neoadjuvant therapy among rectal cancer patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers

      Zachary S. Morris, Sandeep Saha, William J. Magnuson, Brett A. Morris, Jenna F. Borkenhagen, Alisa Ching, Gayle Hirose, Vanesa McMurry, David M. Francis, Paul M. Harari, Rick Chappell, Stuart Tsuji and Mark A. Ritter

      Version of Record online: 20 MAY 2016 | DOI: 10.1002/cncr.30079

      • image
      • image

      The incidental use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers among rectal cancer patients receiving neoadjuvant radiotherapy is associated with an increased rate of pathological complete response. This finding is verified in a second independent database, and a multivariate aggregate analysis shows that the use of these medications is a strong predictor of a pathologic complete response.

    11. Hematologic Malignancies
      Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma

      Yago Nieto, Benigno C. Valdez, Peter F. Thall, Roy B. Jones, Wei Wei, Alan Myers, Chitra Hosing, Sairah Ahmed, Uday Popat, Elizabeth J. Shpall, Muzaffar Qazilbash, Alison Gulbis, Paolo Anderlini, Nina Shah, Qaiser Bashir, Amin Alousi, Yasuhiro Oki, Michelle Fanale, Bouthaina Dabaja, Chelsea Pinnix, Richard Champlin and Borje S. Andersson

      Version of Record online: 20 MAY 2016 | DOI: 10.1002/cncr.30100

      • image
      • image

      With the objective of developing more active high-dose chemotherapy for patients with refractory or high-risk relapsed lymphomas, infusional gemcitabine/busulfan/melphalan is combined with vorinostat and azacitidine (which enhanced antitumor activity in preclinical work). This clinical trial demonstrates that double epigenetic modulation of high-dose chemotherapy is safe and highly active in patients with refractory lymphomas.

    12. Discipline

      Radiation Oncology
      Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT)

      Anthony C. Wong, Sydeaka P. Watson, Sean P. Pitroda, Christina H. Son, Lauren C. Das, Melinda E. Stack, Abhineet Uppal, Go Oshima, Nikolai N. Khodarev, Joseph K. Salama, Ralph R. Weichselbaum and Steven J. Chmura

      Version of Record online: 20 MAY 2016 | DOI: 10.1002/cncr.30058

      • image
      • image
      • image

      Predictors of outcomes in oligometastatic patients treated with ablative stereotactic radiotherapy (SBRT) are poorly defined. We report that breast cancer histology and slow progression are associated with longer survival in this long-term update of a prospective SBRT dose escalation trial, and we propose a microRNA classifier that may help select oligometastatic patients with better prognosis.

    13. Psychosocial Oncology
      Peer-counseling for women newly diagnosed with breast cancer: A randomized community/research collaboration trial

      Janine Giese-Davis, Caroline Bliss-Isberg, Lynne Wittenberg, Jennifer White, Path Star, Lihong Zhong, Matthew J. Cordova, Debra Houston and David Spiegel

      Version of Record online: 19 MAY 2016 | DOI: 10.1002/cncr.30036

      • image
      • image

      The findings of the current randomized controlled trial indicate that, compared with controls, a peer-counseling intervention significantly improves quality of life and maintains marital adjustment in patients with breast cancer. Having a peer counselor may prevent or improve psychosocial morbidity after diagnosis.

  8. Correspondence

    1. Reply to the association between religion/spirituality and mental health in cancer

      John M. Salsman, James E. Pustejovsky, Crystal L. Park, Allen C. Sherman, Thomas V. Merluzzi, Suzanne C. Danhauer, Heather S.L. Jim and George Fitchett

      Version of Record online: 19 MAY 2016 | DOI: 10.1002/cncr.30019

  9. Original Articles

    1. Discipline

      Clinical Trials
      A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies

      Rana R. McKay, Guillermo De Velasco, Lillian Werner, Joaquim Bellmunt, Lauren Harshman, Christopher Sweeney, Jonathan E. Rosenberg, Michelle Hirsch, Sabina Signoretti, Eliezer M. Van Allen, Meghara Walsh, Ulka Vaishampayan, David F. McDermott and Toni K. Choueiri

      Version of Record online: 19 MAY 2016 | DOI: 10.1002/cncr.30056

      • image
      • image

      The phosphatidylinositol-3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is dysregulated in patients with metastatic renal cell carcinoma (mRCC), and targeting this pathway, in addition to the vascular endothelial growth factor (VEGF) pathway, is a potential therapeutic strategy in the management of RCC. Buparlisib at a dose of 80 mg/day with bevacizumab appears to be a tolerable regimen with preliminary activity in patients with vascular endothelial growth factor-refractory mRCC.

  10. Review Articles

    1. Role of isolated limb perfusion with recombinant human tumor necrosis factor α and melphalan in locally advanced extremity soft tissue sarcoma

      Jens Jakob and Peter Hohenberger

      Version of Record online: 19 MAY 2016 | DOI: 10.1002/cncr.29991

      • image
      • image
      • image

      Isolated limb perfusion with recombinant human tumor necrosis factor α and melphalan is a highly effective regional treatment for locally advanced soft tissue sarcoma. This review critically discusses the indication for isolated limb perfusion with recombinant human tumor necrosis factor α and melphalan.

  11. Original Articles

    1. Disease Site

      Hepatobiliary Disease
      Race/ethnicity-specific disparities in cancer incidence, burden of disease, and overall survival among patients with hepatocellular carcinoma in the United States

      John Ha, Melissa Yan, Maria Aguilar, Taft Bhuket, Michele M. Tana, Benny Liu, Robert G. Gish and Robert J. Wong

      Version of Record online: 19 MAY 2016 | DOI: 10.1002/cncr.30103

      • image
      • image
      • image
      • image

      Asians have the highest incidence and prevalence of hepatocellular carcinoma (HCC) in the United States. Although non-Hispanic whites, blacks, and Hispanics all had increasing incidence of HCC from 2003 to 2011, Asians had a declining incidence and a shift from advanced HCC to earlier stage HCC as a result of improved HCC screening and surveillance efforts. See also pages 000-000.

    2. Head and Neck Disease
      Capecitabine and lapatinib for the first-line treatment of metastatic/recurrent head and neck squamous cell carcinoma

      Jared M. Weiss, Stephen Bagley, Wei-Ting Hwang, Joshua Bauml, Juneko Grilley Olson, Roger B. Cohen, David Neil Hayes and Corey Langer

      Version of Record online: 19 MAY 2016 | DOI: 10.1002/cncr.30067

      • image
      • image

      In the current study, patients receiving first-line treatment of metastatic/recurrent head and neck squamous cell cancer were treated with the all-oral regimen of capecitabine and lapatinib. The median progression-free survival was 4.2 months and the median overall survival was 10.7 months.

  12. Editorial

    1. Hepatocellular carcinoma: How can we move from racial/ethnic disparities to a model of health equity?

      Amit G. Singal and Adam C. Yopp

      Version of Record online: 19 MAY 2016 | DOI: 10.1002/cncr.30099

      A study by Ha and colleagues in this issue adds to the evidence base demonstrating racial and ethnic health disparities in health care. However, the evidence base for developing interventions to eliminate these disparities is limited, largely because of a lack of granularity in the available administrative data sets. See also pages 000-000.

  13. Original Articles

    1. Discipline

      Clinical Trials
      Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma

      Robert Z. Orlowski, Arnon Nagler, Pieter Sonneveld, Joan Bladé, Roman Hajek, Andrew Spencer, Tadeusz Robak, Anna Dmoszynska, Noemi Horvath, Ivan Spicka, Heather J. Sutherland, Alexander N. Suvorov, Liang Xiu, Andrew Cakana, Trilok Parekh and Jesús F. San-Miguel

      Version of Record online: 18 MAY 2016 | DOI: 10.1002/cncr.30026

      • image
      • image
      • image

      Despite the superior time to progression observed and the early trend in favor of overall survival with bortezomib-pegylated liposomal doxorubicin combination therapy, long-term follow-up reveals that treatment with the bortezomib-pegylated liposomal doxorubicin combination does not improve overall survival compared with bortezomib monotherapy in patients with relapsed or refractory multiple myeloma. See also pages 000-000.

    2. Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors

      Julie N. Graff, Celestia S. Higano, Noah M. Hahn, Matthew H. Taylor, Bin Zhang, Xiaofei Zhou, Karthik Venkatakrishnan, E. Jane Leonard and John Sarantopoulos

      Version of Record online: 18 MAY 2016 | DOI: 10.1002/cncr.30073

      • image
      • image

      Alisertib is an aurora A kinase and may enhance the activity of the taxane docetaxel. The combination of alisertib and taxane is tolerable and shows activity across various cancer types.

  14. Editorial

    1. Death by a thousand cuts: the slow demise of chemotherapy

      Ajay K. Nooka and Sagar Lonial

      Version of Record online: 18 MAY 2016 | DOI: 10.1002/cncr.30024

      Combining cytotoxic agents with novel agents is an inferior treatment option for patients with relapsed/refractory myeloma. Not all combination therapies have the same efficacy, and the agents in the combinations do matter. See also pages 000-000.

  15. Original Articles

    1. Disease Site

      Genitourinary Disease
      Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer

      Aaron D. Falchook, Ramsankar Basak, Jahan J. Mohiuddin and Ronald C. Chen

      Version of Record online: 18 MAY 2016 | DOI: 10.1002/cncr.30049

      • image
      • image
      • image

      Among patients with favorable intermediate-risk prostate cancer, there are no differences in overall survival for men who receive androgen-deprivation therapy with dose-escalated radiotherapy and men who receive dose-escalated radiotherapy alone; these findings remain after stratification by age and comorbidity. Dose-escalated radiotherapy alone without androgen-deprivation therapy may be an appropriate treatment for men with favorable intermediate-risk prostate cancer. See also pages 000-000.

  16. Editorial

    1. Androgen deprivation therapy use and risk of death in men treated with high-dose radiation for intermediate-risk prostate cancer

      Florence K. Keane and Anthony V. D'Amico

      Version of Record online: 18 MAY 2016 | DOI: 10.1002/cncr.30048

      Men with favorable intermediate-risk prostate cancer have excellent outcomes in comparison with men with unfavorable intermediate-risk disease. In this issue of Cancer, Falchook et al report the largest study to date of men with favorable intermediate-risk prostate cancer treated with dose-escalated radiotherapy with or without androgen deprivation therapy. They demonstrate that overall survival is not associated with the use of androgen deprivation therapy and provide level 2 evidence to suggest the exclusion of androgen deprivation therapy in this population. See also pages 000–000.

  17. Original Articles

    1. Discipline

      Disparities Research
      Disparities in cancer treatment among patients infected with the human immunodeficiency virus

      Gita Suneja, Chun Chieh Lin, Edgar P. Simard, Xuesong Han, Eric A. Engels and Ahmedin Jemal

      Version of Record online: 17 MAY 2016 | DOI: 10.1002/cncr.30052

      Human immunodeficiency virus (HIV)-infected patients with cancer in the United States are less likely to receive cancer treatment compared with their uninfected counterparts, even after factoring in differences in insurance status and medical comorbidities. This disparity needs to be addressed as survival from HIV continues to improve and cancer becomes one of the leading causes of death in the HIV population.

    2. Disease Site

      Head and Neck Disease
      Health-related quality of life before and after head and neck squamous cell carcinoma: Analysis of the Surveillance, Epidemiology, and End Results-Medicare Health Outcomes Survey linkage

      Eleni M. Rettig, Gypsyamber D'Souza, Carol B. Thompson, Wayne M. Koch, David W. Eisele and Carole Fakhry

      Version of Record online: 16 MAY 2016 | DOI: 10.1002/cncr.30005

      • image
      • image

      Health-related quality of life decreases progressively and significantly before and after a diagnosis of head and neck squamous cell carcinoma. Higher prediagnosis health-related quality of life predicts improved survival.

    3. Hematologic Malignancies
      Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity

      Philip A. Thompson, Francesco Stingo, Michael J. Keating, Alessandra Ferrajoli, Jan A. Burger, William G. Wierda, Tapan M. Kadia and Susan M. O'Brien

      Version of Record online: 16 MAY 2016 | DOI: 10.1002/cncr.30069

      • image
      • image

      Toxicity, likely immunologically mediated, is the major limitation to achieving long-term remission during first-line treatment with idelalisib plus rituximab for patients with chronic lymphocytic leukemia. Overall survival is favorable despite the high rate of treatment cessation caused by toxicity.

    4. Discipline

      Epidemiology
      Increased incidence but improved median overall survival for biliary tract cancers diagnosed in Ontario from 1994 through 2012: A population-based study

      Jennifer A. Flemming, Jina Zhang-Salomons, Sulaiman Nanji and Christopher M. Booth

      Version of Record online: 16 MAY 2016 | DOI: 10.1002/cncr.30074

      • image
      • image
      • image

      The incidence of biliary tract cancer is increasing in Ontario. However, this increase is associated with an increase in median overall survival and the use of chemotherapy and radiotherapy. Advances in the surgical and medical management of these tumors are hypothesized to account for this improvement in survival.

    5. Outcomes Research
      Influence of the treatment facility volume on the survival of patients with non-Hodgkin lymphoma

      Ronald S. Go, Mohammed Al-Hamadani, Nilay D. Shah, Cynthia S. Crowson, Sara J. Holton and Elizabeth B. Habermann

      Version of Record online: 16 MAY 2016 | DOI: 10.1002/cncr.30038

      • image
      • image

      Non-Hodgkin lymphoma patients treated at higher volume facilities survive longer than those treated at lower volume facilities. This volume-outcome relation persists even after adjustments for case-mix differences.

  18. Review Articles

    1. The role of 5-aminolevulinic acid in enhancing surgery for high-grade glioma, its current boundaries, and future perspectives: A systematic review

      Alireza Mansouri, Sheila Mansouri, Laureen D. Hachem, George Klironomos, Michael A. Vogelbaum, Mark Bernstein and Gelareh Zadeh

      Version of Record online: 16 MAY 2016 | DOI: 10.1002/cncr.30088

      • image

      The use of 5-aminolevulinic acid as a surgical adjunct for high-grade glioma surgery improves tumor visualization and thus enables a greater extent of resection. However, additional adjuncts may be necessary for maximizing specificity of resection and patient safety.

  19. Original Articles

    1. Discipline

      Epidemiology
      Long-term soy consumption and tumor tissue MicroRNA and gene expression in triple-negative breast cancer

      Xingyi Guo, Qiuyin Cai, Pingping Bao, Jie Wu, Wanqing Wen, Fei Ye, Wei Zheng, Ying Zheng and Xiao-Ou Shu

      Version of Record online: 16 MAY 2016 | DOI: 10.1002/cncr.29981

      • image
      • image

      Soy food consumption may influence the risk and prognosis of breast cancer by altering the expression of cancer-related microRNAs and genes.

    2. Pediatric Oncology
      You have full text access to this OnlineOpen article
      Fertility preservation in children, adolescents, and young adults with cancer: Quality of clinical practice guidelines and variations in recommendations

      Anna Font-Gonzalez, Renée L. Mulder, Erik A.H. Loeffen, Julianne Byrne, Eline van Dulmen-den Broeder, Marry M. van den Heuvel-Eibrink, Melissa M. Hudson, Lisa B. Kenney, Jennifer M. Levine, Wim J.E. Tissing, Marianne D. van de Wetering, Leontien C. M. Kremer and on behalf of the PanCareLIFE Consortium

      Version of Record online: 13 MAY 2016 | DOI: 10.1002/cncr.30047

      • image
      • image

      Only approximately one-third of the identified clinical practice guidelines for fertility preservation in children, adolescents, and young adults with cancer were found to be of sufficient quality, and among these, the recommendations varied substantially. This finding supports the need for well-developed and transparent harmonized clinical practice guidelines for children and young adults diagnosed with cancer who are at risk of fertility impairment.

    3. Supportive Care
      You have full text access to this OnlineOpen article
      Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy

      Paul J. Hesketh, Ian D. Schnadig, Lee S. Schwartzberg, Manuel R. Modiano, Karin Jordan, Sujata Arora, Dan Powers and Matti Aapro

      Version of Record online: 13 MAY 2016 | DOI: 10.1002/cncr.30054

      • image
      • image
      • image

      The efficacy of rolapitant, a neurokinin-1 receptor antagonist with a long duration of action, was examined in a subgroup of 401 patients with cancer who received carboplatin-based chemotherapy in a phase 3 trial. In this population, a single oral dose of rolapitant (180 mg) combined with granisetron and dexamethasone provided statistically superior protection against chemotherapy-induced nausea and vomiting in the delayed and overall phases in comparison with granisetron and dexamethasone alone, and it was well tolerated.

    4. Clinical Trials
      Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia

      Amir T. Fathi, Daniel J. DeAngelo, Kristen E. Stevenson, Jonathan E. Kolitz, Julie D. Asch, Philip C. Amrein, Eyal C. Attar, David P. Steensma, Martha Wadleigh, Julia Foster, Christine Connolly, Ilene Galinsky, Craig E. Devoe, Richard M. Stone, Donna S. Neuberg and Karen K. Ballen

      Version of Record online: 12 MAY 2016 | DOI: 10.1002/cncr.30037

      • image
      • image
      • image

      The intensification of chemotherapy for older patients with acute lymphoblastic leukemia can result in improved outcomes in comparison with historical data. Intensification may be appropriate for sufficiently robust older patients with Philadelphia chromosome–negative acute lymphoblastic leukemia.

    5. Radiation Oncology
      Use of stereotactic body radiotherapy for prostate cancer in the United States from 2004 through 2012

      Brock R. Baker, Ramsankar Basak, Jahan J. Mohiuddin and Ronald C. Chen

      Version of Record online: 12 MAY 2016 | DOI: 10.1002/cncr.30034

      • image

      To the authors' knowledge, the current study is the first to report on the adoption of stereotactic body radiotherapy (SBRT) for patients with localized prostate cancer across the United States. The adoption of SBRT appears to be highest in patients with low-risk or intermediate-risk disease, a finding that is in accordance with the bulk of patients included in published SBRT studies.

  20. Review Articles

    1. Improving the quality of survivorship for older adults with cancer

      Supriya G. Mohile, Arti Hurria, Harvey J. Cohen, Julia H. Rowland, Corinne R. Leach, Neeraj K. Arora, Beverly Canin, Hyman B. Muss, Allison Magnuson, Marie Flannery, Lisa Lowenstein, Heather G. Allore, Karen M. Mustian, Wendy Demark-Wahnefried, Martine Extermann, Betty Ferrell, Sharon K. Inouye, Stephanie A. Studenski and William Dale

      Version of Record online: 12 MAY 2016 | DOI: 10.1002/cncr.30053

      Research priorities for older adults with cancer include the development and implementation of intervention trials. Trials for older adults with cancer should: 1) rigorously test interventions to prevent the decline of or improve health status, especially interventions focused on optimizing physical performance, nutritional status, and cognition while undergoing cancer treatment; 2) use standardized care plans based on geriatric assessment findings to guide targeted interventions; and 3) incorporate the principles of geriatrics into survivorship care plans.

  21. Original Articles

    1. Discipline

      Supportive Care
      Refinement and revalidation of the demoralization scale: The DS-II—internal validity

      Sophie Robinson, David. W. Kissane, Joanne Brooker, Natasha Michael, Jane Fischer, Michael Franco, Courtney Hempton, Merlina Sulistio, Julie F. Pallant, David M. Clarke and Sue Burney

      Version of Record online: 12 MAY 2016 | DOI: 10.1002/cncr.30015

      • image
      • image
      • image
      • image

      The Demoralization Scale-II is a self-report scale comprising 16 items and 2 components. It is an improved and more practically attractive measure of demoralization. See also pages 000–000.

    2. Disease Site

      Neuro-Oncology
      Concurrent chemoradiotherapy versus radiotherapy alone for “biopsy-only” glioblastoma multiforme

      Adam J. Kole, Henry S. Park, Debra N. Yeboa, Charles E. Rutter, Christopher D. Corso, Sanjay Aneja, Nataniel H. Lester-Coll, Brandon R. Mancini, Jonathan P. Knisely and James B. Yu

      Version of Record online: 12 MAY 2016 | DOI: 10.1002/cncr.30063

      • image
      • image

      Data are limited regarding optimal treatments for patients who undergo “biopsy-only” for glioblastoma multiforme. Outcomes after concurrent chemoradiotherapy versus radiotherapy alone are examined for “biopsy-only” glioblastoma multiforme using a large national database.

  22. Editorial

    1. Demoralization syndrome: New insights in psychosocial cancer care

      Luigi Grassi and Maria Giulia Nanni

      Version of Record online: 12 MAY 2016 | DOI: 10.1002/cncr.30022

      Demoralization is confirmed as a significant clinical dimension that needs to be part of the vision physicians should have when treating cancer patients. It is not a psychiatric disease but the expression of an unfolding, situational existence already involved in an irreducibly complex social world, in which cancer and its consequences as traumatic stressors impact the patient's experience and feelings, inducing a profound sense of emotional suffering. See also pages 000-000.

  23. Original Articles

    1. Discipline

      Supportive Care
      Refinement and revalidation of the demoralization scale: The DS-II—external validity

      Sophie Robinson, David. W. Kissane, Joanne Brooker, Courtney Hempton, Natasha Michael, Jane Fischer, Michael Franco, Merlina Sulistio, David M. Clarke, Mehmet Ozmen and Susan Burney

      Version of Record online: 12 MAY 2016 | DOI: 10.1002/cncr.30012

      The Demoralization Scale-II demonstrates convergent and discriminant validity. A difference of 2 points in scores on the Demoralization Scale-II may be clinically meaningful. See also pages 000-000.

  24. Editorial

    1. Filling the gaps in knowledge and treatments for sexual health in young adult male cancer survivors

      Karen L. Syrjala

      Version of Record online: 12 MAY 2016 | DOI: 10.1002/cncr.29988

      Male survivors of childhood cancer will spend their entire adult lives with the late effects of treatment on their sexual health. A valuable article in this issue makes it clear that the sexual difficulties in these survivors, who most often are treated for hematologic malignancies like acute lymphoblastic leukemia, differ from those in men who are treated for prostate or testicular cancer, and their sexual function treatments must be adapted to fit those needs. See also pages 000-000.

  25. Original Articles

    1. Discipline

      Survivorship
      Sexual function in male long-term survivors of childhood acute lymphoblastic leukemia

      Anu Haavisto, Markus Henriksson, Risto Heikkinen, Leena-Riitta Puukko-Viertomies and Kirsi Jahnukainen

      Version of Record online: 12 MAY 2016 | DOI: 10.1002/cncr.29989

      • image

      Male adult long-term survivors of childhood acute lymphoblastic leukemia report lower sexual functioning than controls, with current depressive symptoms, the absence of a relationship and, to a smaller extent, testicular size as an indication of gonadal damage from childhood antileukemia therapy as the most important predictive factors. There is a deeper decline in sexual functioning in the oldest age group of survivors compared with a control group. See also pages 000-000.

    2. Disease Site

      Hematologic Malignancies
      Changes in the survival of older patients with hematologic malignancies in the early 21st century

      Dianne Pulte, Lina Jansen, Felipe A. Castro and Hermann Brenner

      Version of Record online: 10 MAY 2016 | DOI: 10.1002/cncr.30003

      • image
      • image
      • image
      • image

      Five-year relative survival has increased for older patients in the early 21st century for most common hematologic malignancies, but it continues to be lower than that for younger patients. This age-related disparity is decreasing for lymphomas.

    3. Discipline

      Clinical Trials
      Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508)

      Chandra P. Belani, Suzanne E. Dahlberg, Charles M. Rudin, Martin Fleisher, Helen X. Chen, Naoko Takebe, Mario R. Velasco Jr, William J. Tester, Keren Sturtz, Christine L. Hann, James C. Shanks, Manish Monga, Suresh S. Ramalingam and Joan H. Schiller

      Version of Record online: 10 MAY 2016 | DOI: 10.1002/cncr.30062

      • image
      • image
      • image
      • image

      The addition of vismodegib or cixutumumab to cisplatin and etoposide for patients with extensive-stage small cell lung cancer does not demonstrate an overall benefit. A low baseline circulating tumor cell count is associated with an overall favorable prognosis for patients with extensive-stage small cell lung cancer.

    4. Disease Site

      Genitourinary Disease
      Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial

      Douglas K. Price, Cindy H. Chau, Cathee Till, Phyllis J. Goodman, Robin J. Leach, Teresa L. Johnson-Pais, Ann W. Hsing, Ashraful Hoque, Howard L. Parnes, Jeannette M. Schenk, Catherine M. Tangen, Ian M. Thompson, Juergen K. V. Reichardt and William D. Figg

      Version of Record online: 10 MAY 2016 | DOI: 10.1002/cncr.30071

      • image

      This case-control study from the Prostate Cancer Prevention Trial study demonstrates the significance of androgen metabolism in prostate cancer and suggests that genetic variations along the androgen pathway modify serum hormone concentrations, contributing to the risk of prostate cancer, and that subgroups of men may be more susceptible to the disease. Findings from this study provide further insight into the genetic etiology of the increased risk of high-grade cancer among men who receive treatment with finasteride.

  26. Commentary

    1. Understanding the value of cancer drugs–the devil is in the detail

      Daniel A. Goldstein

      Version of Record online: 10 MAY 2016 | DOI: 10.1002/cncr.30044

      New tools to assess the value of cancer drugs are not sufficiently detailed. Economic modeling provides the ideal method with which to assess their value.

  27. Original Articles

    1. Discipline

      Survivorship
      Is it my cancer or am i just getting older?: Impact of cancer on age-related health conditions of older cancer survivors

      Corinne R. Leach, Keith M. Bellizzi, Arti Hurria and Bryce B. Reeve

      Version of Record online: 9 MAY 2016 | DOI: 10.1002/cncr.29914

      The current prospective study examines the impact of cancer on the functioning, development of, and worsening of age-related health conditions among older adults who develop cancer compared with age-matched controls. The findings suggest that cancer is a stronger driver for declines in physical functioning and an increased risk of depression in older adults.

    2. Disease Site

      Hematologic Malignancies
      Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma

      Jonathon B. Cohen, Xuesong Han, Ahmedin Jemal, Elizabeth M. Ward and Christopher R. Flowers

      Version of Record online: 6 MAY 2016 | DOI: 10.1002/cncr.30068

      • image
      • image

      According to a national cohort analysis, patients who defer therapy for at least 90 days after the diagnosis of mantle cell lymphoma have improved survival. Patients who do not have comorbidities and lack aggressive disease features may be candidates for deferred therapy.

    3. Gastrointestinal Disease
      A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy

      Qi Qi, Liping Zhuang, Yehua Shen, Yawen Geng, Shulin Yu, Hao Chen, Luming Liu, Zhiqiang Meng, Peng Wang and Zhen Chen

      Version of Record online: 6 MAY 2016 | DOI: 10.1002/cncr.30057

      • image
      • image
      • image
      • image
      • image

      The authors describe their development of a systemic inflammation response index based on peripheral neutrophil, monocyte, and lymphocyte counts. The index can be used to predict the survival of patients with pancreatic adenocarcinoma who receive chemotherapy.

    4. Discipline

      Medical Oncology
      Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma

      Geoffrey Y. Ku, Anuja Kriplani, Yelena Y. Janjigian, David P. Kelsen, Valerie W. Rusch, Manjit Bains, Joanne Chou, Marinela Capanu, Abraham J. Wu, Karyn A. Goodman and David H. Ilson

      Version of Record online: 6 MAY 2016 | DOI: 10.1002/cncr.30028

      • image

      This retrospective review of 201 patients with locally advanced esophageal adenocarcinoma treated with induction chemotherapy and preoperative chemoradiation confirms that a positron emission tomography (PET) assessment after induction chemotherapy strongly predicts outcomes, with PET nonresponders to chemotherapy having very poor outcomes. The data suggest that PET nonresponders who receive alternative chemotherapy during radiation can have significantly improved progression-free survival in comparison with PET nonresponders who continue with the same chemotherapy during radiation, and trends toward an improved pathologic complete response and overall survival may also be possible.

    5. Epidemiology
      Risk of second gonadal cancers in women and children with germ cell tumors

      Zi Wei Liao, Maria Clarissa Rodrigues, Jenny N. Poynter, James F. Amatruda, Carlos Rodriguez-Galindo and A. Lindsay Frazier

      Version of Record online: 6 MAY 2016 | DOI: 10.1002/cncr.30014

      Postpubertal boys and men with germ cell tumors share a similar risk of developing a second testicular cancer. However, neither prepubertal boys with testicular cancer nor females with ovarian germ cell tumors appear to have an increased risk of second gonadal cancer.

  28. Review Articles

    1. The potential impact of prophylactic human papillomavirus vaccination on oropharyngeal cancer

      Theresa Guo, David W. Eisele and Carole Fakhry

      Version of Record online: 6 MAY 2016 | DOI: 10.1002/cncr.29992

      • image
      • image
      • image

      Prophylactic human papillomavirus vaccines are approved by the US Food and Drug Administration for the prevention of anogenital precancer, cancer, and warts. A growing subset of oropharyngeal cancers are related to infection with the human papillomavirus. In the absence of data regarding prevention, the potential efficacy of these vaccines in the oropharynx is reviewed here.

  29. Correspondence

  30. Original Articles

    1. Discipline

      Epidemiology
      Prediagnostic aspirin use and mortality in women with stage I to III breast cancer: A cohort study in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial

      Marie C. Bradley, Amanda Black, Andrew N. Freedman and Thomas I. Barron

      Version of Record online: 3 MAY 2016 | DOI: 10.1002/cncr.30004

      • image
      • image

      There is a growing body of evidence that aspirin may reduce the risk of cancer mortality; however, the precise mechanism of action remains unclear. The results of the current study demonstrate, for what to the authors' knowledge is the first time, a statistically significant interaction between lymph node status at the time of diagnosis and prediagnostic aspirin use. The absence of metastasis at the time of diagnosis may indicate patients whose breast tumors have responded to prediagnostic aspirin use, and consequently is predictive of a survival benefit from aspirin use in these patients.

    2. Disease Site

      Hematologic Malignancies
      Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis

      Morie A. Gertz, Martha Q. Lacy, Angela Dispenzieri, Francis K. Buadi, David Dingli, Suzanne R. Hayman, Shaji K. Kumar, Nelson Leung, John Lust, S. Vincent Rajkumar, Stephen J. Russell, Vera J. Suman, Jennifer G. Le-Rademacher and William J. Hogan

      Version of Record online: 3 MAY 2016 | DOI: 10.1002/cncr.30051

      • image
      • image
      • image
      • image

      Eighty-nine patients with biopsy-proven light-chain amyloidosis were allowed to select treatment with melphalan plus dexamethasone (n = 34) or stem cell transplantation (n = 55). Twenty-four matched triplet sets (2 stem cell transplant patients for each melphalan-dexamethasone patient) showed no difference in hematologic response, but survival was better after autologous stem cell transplantation.

    3. Discipline

      Psychosocial Oncology
      “Being a good patient” during times of illness as defined by adolescent patients with cancer

      Meaghann S. Weaver, Justin N. Baker, Jami S. Gattuso, Deborah V. Gibson and Pamela S. Hinds

      Version of Record online: 3 MAY 2016 | DOI: 10.1002/cncr.30033

      • image
      • image

      Adolescents with cancer consider relational roles in their medical interactions, citing the opinions of others and impact on others as formative for their care preferences and decisions. This face-to-face interview study describes “good patient” and “good child” terms through interviews with 40 adolescent oncology patients. The adolescents' description of the concepts plus the behaviors of parents and professionals is reported. The study reports on parental actions and clinician behaviors perceived by adolescents with cancer as supportive in helping them to achieve their good child and good patient definitions.

    4. Disease Site

      Hematologic Malignancies
      Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from two phase 2 studies

      Hagop M. Kantarjian, Anthony S. Stein, Ralf C. Bargou, Carlos Grande Garcia, Richard A. Larson, Matthias Stelljes, Nicola Gökbuget, Gerhard Zugmaier, Jonathan E. Benjamin, Alicia Zhang, Catherine Jia and Max S. Topp

      Version of Record online: 3 MAY 2016 | DOI: 10.1002/cncr.30031

      • image

      Older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia typically have a worse prognosis and fewer therapy options compared with younger patients. In this analysis of pooled data from two phase 2 studies of single-agent blinatumomab therapy in patients with this disease, older (aged ≥65 years) and younger (aged <65 years) adults had similar treatment outcomes.

    5. Gastrointestinal Disease
      Treatment allocation in patients with early-stage esophageal adenocarcinoma: Prevalence and predictors of lymph node involvement

      Anthony M. Gamboa, Sungjin Kim, Seth D. Force, Charles A. Staley, Kevin E. Woods, David A. Kooby, Shishir K. Maithel, Jennifer A. Luke, Katherine M. Shaffer, Sunil Dacha, Nabil F. Saba, Steven A. Keilin, Qiang Cai, Bassel F. El-Rayes, Zhengjia Chen and Field F. Willingham

      Version of Record online: 3 MAY 2016 | DOI: 10.1002/cncr.30040

      • image
      • image
      • image

      In a large national sample of patients with early, low-grade esophageal cancers, the prevalence of lymph node metastasis is low. For selected patients, these data support the use of local endoscopic surgical resection as an alternative to surgical management.

    6. Genitourinary Disease
      Prostate tumor DNA methylation is associated with cigarette smoking and adverse prostate cancer outcomes

      Irene M. Shui, Chao-Jen Wong, Shanshan Zhao, Suzanne Kolb, Ericka M. Ebot, Milan S. Geybels, Rohina Rubicz, Jonathan L. Wright, Daniel W. Lin, Brandy Klotzle, Marina Bibikova, Jian-Bing Fan, Elaine A. Ostrander, Ziding Feng and Janet L. Stanford

      Version of Record online: 3 MAY 2016 | DOI: 10.1002/cncr.30045

      • image
      • image

      This unique analysis integrates smoking status, tumor DNA methylation, tumor gene expression, and long-term follow-up for prostate cancer outcomes. The results support the hypothesis that smoking-associated tumor DNA methylation changes may explain at least part of the association between smoking and adverse prostate cancer outcomes.

  31. Correspondence

  32. Original Articles

    1. Disease Site

      Hematologic Malignancies
      The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia

      Jessica R. Galloway-Peña, Daniel P. Smith, Pranoti Sahasrabhojane, Nadim J. Ajami, W. Duncan Wadsworth, Naval G. Daver, Roy F. Chemaly, Lisa Marsh, Shashank S. Ghantoji, Naveen Pemmaraju, Guillermo Garcia-Manero, Katayoun Rezvani, Amin M. Alousi, Jennifer A. Wargo, Elizabeth J. Shpall, Phillip A. Futreal, Michele Guindani, Joseph F. Petrosino, Dimitrios P. Kontoyiannis and Samuel A. Shelburne

      Version of Record online: 3 MAY 2016 | DOI: 10.1002/cncr.30039

      • image
      • image
      • image
      • image

      Correlations between microbiome composition and infectious outcomes in patients with acute myeloid leukemia (AML) undergoing induction chemotherapy were investigated. The results indicate that longitudinal analyses and measurements of oral and stool microbiomes in patients with AML can assist with risk assessment or mitigation of infectious complications during AML therapy.

    2. Discipline

      Disparities Research
      Racial and ethnic disparities in human papillomavirus-associated cancer burden with first-generation and second-generation human papillomavirus vaccines

      Emily A. Burger, Kyueun Lee, Mona Saraiya, Trevor D. Thompson, Harrell W. Chesson, Lauri E. Markowitz and Jane J. Kim

      Version of Record online: 28 APR 2016 | DOI: 10.1002/cncr.30007

      • image
      • image

      Human papillomavirus vaccines are expected to reduce the overall burden of human papillomavirus-associated cancers for all racial/ethnic groups as well as reduce the absolute disparity gap. However, even with improved coverage with the second-generation vaccine, relative racial/ethnic disparities will likely still exist and may widen if the underlying causes of these disparities remain unaddressed.

    3. Disease Site

      Head and Neck Disease
      Confirmation of proposed human papillomavirus risk–adapted staging according to AJCC/UICC TNM criteria for positive oropharyngeal carcinomas

      Zachary D. Horne, Scott M. Glaser, John A. Vargo, Robert L. Ferris, Goundappa K. Balasubramani, David A. Clump, Dwight E. Heron and Sushil Beriwal

      Version of Record online: 25 APR 2016 | DOI: 10.1002/cncr.30021

      • image
      • image
      • image
      • image
      • image
      • image

      The current American Joint Commission on Cancer staging system for human papillomavirus–positive oropharyngeal cancers does not accurately reflect disease outcomes. This large, registry-based, retrospective study validates a recently proposed human papillomavirus risk–adapted restaging structure for more accurately risk-stratifying patients on the basis of their observed outcomes.

  33. Correspondence

  34. Original Articles

    1. Discipline

      Psychosocial Oncology
      The relationship between coping strategies, quality of life, and mood in patients with incurable cancer

      Ryan D. Nipp, Areej El-Jawahri, Joel N. Fishbein, Justin Eusebio, Jamie M. Stagl, Emily R. Gallagher, Elyse R. Park, Vicki A. Jackson, William F. Pirl, Joseph A. Greer and Jennifer S. Temel

      Version of Record online: 18 APR 2016 | DOI: 10.1002/cncr.30025

      • image

      Patients with a new diagnosis of incurable cancer cope in a variety of unique ways. Patients' use of certain coping strategies correlate with their quality of life and mood, and this suggests that evaluating and addressing patients' coping behaviors may affect other key patient-reported outcomes.

    2. Epidemiology
      Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009

      Dorothee Gramatzki, Silvia Dehler, Elisabeth Jane Rushing, Kathrin Zaugg, Silvia Hofer, Yasuhiro Yonekawa, Helmut Bertalanffy, Anton Valavanis, Dimitri Korol, Sabine Rohrmann, Miklos Pless, Joachim Oberle, Patrick Roth, Hiroko Ohgaki and Michael Weller

      Version of Record online: 18 APR 2016 | DOI: 10.1002/cncr.30023

      • image
      • image

      Population-based studies of glioblastoma are scarce and traditionally have suffered from methodological limitations. In the current study, the authors demonstrate that, on a population level, the overall survival of patients with glioblastoma diagnosed in the Canton of Zurich in Switzerland has markedly improved from the pre-temozolomide to the temozolomide era. Age, Karnofsky performance score, extent of tumor resection, first-line treatment regimens, and, as demonstrated for the first time, MGMT promoter methylation status as well as isocitrate dehydrogenase 1R132H mutation status are associated with survival today.

    3. Outcomes Research
      Comparative effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for patients with brain metastases from breast or non–small cell lung cancer

      Lia M. Halasz, Hajime Uno, Melissa Hughes, Thomas D'Amico, Elisabeth U. Dexter, Stephen B. Edge, James A. Hayman, Joyce C. Niland, Gregory A. Otterson, Katherine M. W. Pisters, Richard Theriault, Jane C. Weeks and Rinaa S. Punglia

      Version of Record online: 18 APR 2016 | DOI: 10.1002/cncr.30009

      • image
      • image
      • image

      With data from a multi-institutional, longitudinal database, propensity score analyses have been performed for patients treated for brain metastases from non–small cell lung cancer or breast cancer. Patients treated initially for fewer than 4 brain metastases with stereotactic radiosurgery alone have improved survival.

    4. Disease Site

      Gastrointestinal Disease
      Changes in treatment patterns for patients with locally advanced rectal cancer in the United States over the past decade: An analysis from the National Cancer Data Base

      Helmneh M. Sineshaw, Ahmedin Jemal, Charles R. Thomas Jr and Timur Mitin

      Version of Record online: 13 APR 2016 | DOI: 10.1002/cncr.29993

      • image
      • image

      Analysis of the National Cancer Data Base revealed that over the past decade, the adoption of neoadjuvant chemoradiotherapy has been increasing in the United States for patients with locally advanced rectal cancer. Unfortunately, only approximately one-half of US patients currently receive the standard care with trimodality therapy, which is in part related to socioeconomic factors.

    5. Discipline

      Psychosocial Oncology
      Institutional capacity to provide psychosocial oncology support services: A report from the Association of Oncology Social Work

      Brad Zebrack, Karen Kayser, Lynne Padgett, Laura Sundstrom, Chad Jobin, Krista Nelson and Iris C. Fineberg

      Version of Record online: 12 APR 2016 | DOI: 10.1002/cncr.30016

      • image
      • image
      • image

      The results of this study suggest that cancer programs in the United States are performing moderately well in terms of the provision of psychosocial care. Variations in psychosocial service capacity appear to be a function of patient, provider, and system characteristics. See also pages 000-000.

    6. Disease Site

      Hematologic Malignancies
      The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group

      Holly L. Geyer, Bjorn Andreasson, Heidi E. Kosiorek, Amylou C. Dueck, Robyn M. Scherber, Kari A. Martin, Kristina A. Butler, Claire N. Harrison, Deepti H. Radia, Francisco Cervantes, Jean-Jacques Kiladjian, Andreas Reiter, Gunnar Birgegard, Francesco Passamonti, Zhenya Senyak, Alessandro M. Vannucchi, Chiara Paoli, Zhijian Xiao, Jan Samuelsson and Ruben A. Mesa

      Version of Record online: 12 APR 2016 | DOI: 10.1002/cncr.30013

      • image

      Sexuality problems impact all domains of functionality, depression, microvascular symptoms, and overall quality of life among patients with myeloproliferative neoplasms. These problems correlate with patient age, the presence of cytopenias, transfusion requirements, and common therapies for myeloproliferative neoplasms.

  35. Editorial

    1. Let's talk about sex[uality]-related symptom burden in myeloproliferative neoplasms

      Aaron T. Gerds

      Version of Record online: 12 APR 2016 | DOI: 10.1002/cncr.30017

      A thoughtful conversation about sexual symptom burden should occur as part of a comprehensive assessment of the overall well-being of patients with myeloproliferative neoplasms. In the article by Geyer et al in this issue of Cancer, the authors quantify the sexuality-related symptoms, along with quality of life, in patients with myeloproliferative neoplasms, and evaluate how they correspond to disease features and treatment.

    2. Quality of psychosocial services in cancer centers: Today and tomorrow

      William F. Pirl and Inga T. Lennes

      Version of Record online: 12 APR 2016 | DOI: 10.1002/cncr.30018

      Data from Zebrack et al's survey of 57 cancer centers in the United States and Canada have led the authors to conclude that cancers centers are performing moderately well in communicating the importance of psychosocial care, identifying patient psychosocial needs, and referring patients to services. This editorial focuses on areas that need further work and places the data in the context of the process of changing practice to improve the quality of care.See also pages 000-000.

  36. Original Articles

    1. Discipline

      Pediatric Oncology
      Nonrandomized comparison of neurofibromatosis type 1 and non–neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: A report from the Children's Oncology Group

      Joann L. Ater, Caihong Xia, Claire M. Mazewski, Timothy N. Booth, David R. Freyer, Roger J. Packer, Richard Sposto, Gilbert Vezina and Ian F. Pollack

      Version of Record online: 8 APR 2016 | DOI: 10.1002/cncr.29987

      • image
      • image
      • image
      • image

      Children with neurofibromatosis type 1 who are treated for low-grade gliomas tolerate carboplatin and vincristine well and have tumor response rates and event-free survival superior to those for children without neurofibromatosis type 1.

    2. Disease Site

      Breast Disease
      You have full text access to this OnlineOpen article
      Updated results of the Gothenburg Trial of Mammographic Screening

      Nils G. Bjurstam, Lena M. Björneld and Stephen W. Duffy

      Version of Record online: 8 APR 2016 | DOI: 10.1002/cncr.29975

      • image

      In a randomized trial of breast cancer screening, a significant reduction in breast cancer mortality is found with the offer of mammographic screening. The results suggest that screening can be effective in women younger than 50 years.

    3. Gynecologic Oncology
      Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy

      Ursula A. Matulonis, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra, Daniela Matei, Anitra Fielding, Stuart Spencer, David Parry, Lynda Grinsted and Jonathan A. Ledermann

      Version of Record online: 8 APR 2016 | DOI: 10.1002/cncr.29995

      • image
      • image
      • image
      • image

      Maintenance therapy with olaparib, a poly(adenosine diphosphate ribose) polymerase inhibitor, in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation significantly improves progression-free survival in comparison with a placebo, according to an interim analysis. However, BRCA mutation carriers receiving a placebo who switch to a poly(adenosine diphosphate ribose) polymerase inhibitor after disease progression are suggested by a post hoc analysis to have a confounding influence on the interim overall survival analysis.

    4. Discipline

      Outcomes Research
      Risk of brain metastases in patients with nonmetastatic lung cancer: Analysis of the Metropolitan Detroit Surveillance, Epidemiology, and End Results (SEER) data

      Priscila H. Goncalves, Stephanie L. Peterson, Fawn D. Vigneau, Ronald D. Shore, William O. Quarshie, Khairul Islam, Ann G. Schwartz, Antoinette J. Wozniak and Shirish M. Gadgeel

      Version of Record online: 8 APR 2016 | DOI: 10.1002/cncr.30000

      • image
      • image

      Brain metastases remain an important cause of morbidity and mortality in patients with lung cancer The results of the current study demonstrate that the incidence of brain metastases in patients with nonmetastatic lung cancer varies according to histology, age, and sex in data obtained from a diagnosis period spanning 39 years.

    5. Disease Site

      Hepatobiliary Disease
      Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation

      Atsuya Takeda, Naoko Sanuki, Yuichiro Tsurugai, Shogo Iwabuchi, Kotaro Matsunaga, Hirotoshi Ebinuma, Kento Imajo, Yousuke Aoki, Hidetsugu Saito and Etsuo Kunieda

      Version of Record online: 8 APR 2016 | DOI: 10.1002/cncr.30008

      • image
      • image

      Stereotactic body radiotherapy achieves high local control (3-year local control rate, 96.3%) and overall survival with acceptable toxicities for patients who have a solitary hepatocellular carcinoma (HCC), despite rather stringent conditions. Stereotactic body radiotherapy can be effective against solitary HCC in treatment-naive, intrahepatic failure, residual disease, and recurrent settings, taking advantage of its distinctive characteristics.

    6. Discipline

      Disparities Research
      You have full text access to this OnlineOpen article
      Accuracy of advanced cancer patients' life expectancy estimates: The role of race and source of life expectancy information

      Kelly M. Trevino, Baohui Zhang, Megan J. Shen and Holly G. Prigerson

      Version of Record online: 29 MAR 2016 | DOI: 10.1002/cncr.30001

      • image
      • image

      The majority of advanced cancer patients have an inaccurate understanding of their life expectancy and do not rely on medical providers for information on life expectancy. Black patients are less likely than white patients to have an accurate understanding of their life expectancy and to rely on their medical providers for information on life expectancy.

    7. Disease Site

      Genitourinary Disease
      Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: A randomized clinical trial

      Gustavo Arruda Viani, Bruno Silveira Viana, Jose Eduardo Chicareli Martin, Bruno Tiago Rossi, Gisele Zuliani and Eduardo Jose Stefano

      Version of Record online: 29 MAR 2016 | DOI: 10.1002/cncr.29983

      • image
      • image
      • image
      • image

      This randomized clinical trial is the first head-to-head comparison of intensity-modulated radiotherapy versus 3-dimensional conformal radiotherapy in 215 patients with prostate cancer who received treatment on a hypofractionated schedule. The results reveal a significant reduction in grade ≥2 acute/late gastrointestinal and genitourinary toxicity, a significant improvement in quality-of-life domains in the intensity-modulated radiotherapy arm, and similar biochemical control.

    8. Discipline

      Clinical Trials
      A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer

      Helen Chow, Paramita M. Ghosh, Ralph deVere White, Christopher P. Evans, Marc A. Dall'Era, Stanley A. Yap, Yueju Li, Laurel A. Beckett, Primo N. Lara Jr and Chong-Xian Pan

      Version of Record online: 28 MAR 2016 | DOI: 10.1002/cncr.29927

      • image
      • image
      • image

      The combination of bicalutamide and everolimus achieved a prostate-specific antigen response rate of 75% (95% confidence interval, 0.53-0.90) compared with the historical control of 25% with bicalutamide alone in 24 bicalutamide-naïve patients with castration-resistant prostate cancer.

    9. Disease Site

      Head and Neck Disease
      Treatment trends and survival effects of chemotherapy for hypopharyngeal cancer: Analysis of the National Cancer Data Base

      Phoebe Kuo, Julie A. Sosa, Barbara A. Burtness, Zain A. Husain, Saral Mehra, Sanziana A. Roman, Wendell G. Yarbrough and Benjamin L. Judson

      Version of Record online: 28 MAR 2016 | DOI: 10.1002/cncr.29962

      • image
      • image
      • image

      In an analysis of patients with hypopharyngeal cancer in the National Cancer Data Base, there has been a significant increase in the use of chemotherapy with radiotherapy both as definitive treatment and in combination with surgery. On multivariate analysis, improved overall survival was noted for chemoradiotherapy compared with radiation alone in the definitive setting.

    10. Hematologic Malignancies
      Long-term follow-up of patients with acute myeloid leukemia surviving and free of disease recurrence for at least 2 years after autologous stem cell transplantation: A report from the acute leukemia working party of the European Society for Blood and Marrow Transplantation

      Tomasz Czerw, Myriam Labopin, Norbert-Claude Gorin, Sebastian Giebel, Didier Blaise, Giovanna Meloni, Arnaud Pigneux, Alberto Bosi, Joan Veelken, Felicetto Ferrara, Nicolaas Schaap, Roberto M. Lemoli, Jan J. Cornelissen, Eric Beohou, Arnon Nagler and Mohamad Mohty

      Version of Record online: 28 MAR 2016 | DOI: 10.1002/cncr.29990

      • image
      • image
      • image
      • image

      Late disease recurrence remains a major concern for long-term survivors of autologous stem cell transplantation for acute myeloid leukemia. This indicates the need for close monitoring of minimal residual disease and additional leukemic control measures after transplantation.

    11. Genitourinary Disease
      You have full text access to this OnlineOpen article
      Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer

      Shi-Ming Tu, Mehmet Asim Bilen, Kenneth R. Hess, Russell R. Broaddus, Scott Kopetz, Chongjuan Wei, Lance C. Pagliaro, Jose A. Karam, John F. Ward, Christopher G. Wood, Priya Rao, Zachary H. Tu, Rosale General, Adrienne H. Chen, Yago L. Nieto, Sai-ching J. Yeung, Sue-Hwa Lin, Christopher J. Logothetis and Louis L. Pisters

      Version of Record online: 28 MAR 2016 | DOI: 10.1002/cncr.29996

      • image
      • image

      Whether intratumoral heterogeneity is derived from differentiation of aberrant progenitor cells or from mutation of driver genes is investigated in a relevant clinical model, and the results suggest that intratumoral heterogeneity is caused in part by differentiation of pluripotent progenitor cells. Integrated or multimodal therapy may be effective at addressing intratumoral heterogeneity and treating distinct tumor subtypes as well as potentially lethal tumor phenotypes; this finding has profound clinical implications regarding the origin of intratumoral heterogeneity and the implementation of precision medicine in testicular cancer and other solid tumors.

    12. Hematologic Malignancies
      Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies

      Gautam Borthakur, Leslie Popplewell, Michael Boyiadzis, James Foran, Uwe Platzbecker, Norbert Vey, Roland B. Walter, Rebecca Olin, Azra Raza, Aristoteles Giagounidis, Aref Al-Kali, Elias Jabbour, Tapan Kadia, Guillermo Garcia-Manero, John W. Bauman, Yuehui Wu, Yuan Liu, Dan Schramek, Donna S. Cox, Paul Wissel and Hagop Kantarjian

      Version of Record online: 18 MAR 2016 | DOI: 10.1002/cncr.29986

      • image
      • image

      This is the first study to show a link between RAS-mutant myeloid malignancies and clinical responses to mitogen-activated protein kinase kinase inhibitor therapy. These data highlight the importance of the RAS/RAF/mitogen-activated protein kinase pathway in leukemogenesis and support further study of trametinib in patients with RAS-mutant myeloid malignancies.

  37. Review Articles

    1. Caring for caregivers and patients: Research and clinical priorities for informal cancer caregiving

      Erin E. Kent, Julia H. Rowland, Laurel Northouse, Kristin Litzelman, Wen-Ying Sylvia Chou, Nonniekaye Shelburne, Catherine Timura, Ann O'Mara and Karen Huss

      Version of Record online: 17 MAR 2016 | DOI: 10.1002/cncr.29939

      This article reviews current evidence on the state of the science of informal cancer caregiving. Recommendations include improving the prevalence and burden estimation of informal cancer caregiving; advancing the development of interventions designed to improve outcomes for cancer patients, caregivers, and patient-caregiver dyads; generating strategies to integrate caregivers into formal health care settings; and promoting the use of technology to support informal cancer caregivers.

VIEW

  1. 1 - 100
  2. 101 - 106

SEARCH

SEARCH BY CITATION